Jeff Wilkinson

Brain Health for Longevity: What Works? What Doesn't?

Nora Super, Alvaro Fernandez, Sarah Lock, David Perlmutter, Alfred Sandrock, Brian Van Buren, Jeff Wilkinson, Dr. Mark Hyman, Joe Maroon, Mark Fisher

Amidst a rapidly aging U.S. population where one in five residents will be over 65 by 2030, this event examines the convergence of biological mechanisms like autophagy and clinical breakthroughs to address the $716 trillion economic impact of cognitive decline. Panelists discuss a critical shift from late-stage treatment to early prevention, detailing how multimodal interventions—including sleep optimization, vascular health management, and disease-modifying therapies in the DIAN trial—can delay dementia onset by five to ten years. The discussion further emphasizes the necessity of overcoming diagnostic stigma and equity gaps to integrate neurotechnology and community support systems into a comprehensive public health strategy for brain longevity.